Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Immune cell engagers (ICEs) represent a significant advancement in cancer immunotherapy.
• They are designed to activate immune effector cells, including T cells, NK cells, and phagocytes, to target and eliminate tumor cells.
• ICEs address key challenges in cancer treatment, such as immune evasion and MHC downregulation.

Purpose of the Study:

• To review the mechanisms, platforms, research trends, and clinical progress of immune cell engagers.
• To highlight the pivotal role of ICEs in advancing precision immunotherapy.
• To emphasize the potential of ICEs as a cornerstone of next-generation cancer therapies.

Main Methods:

• Review of existing literature on immune cell engagers, including T-cell engagers (TCEs), NK cell engagers (NKCEs), and phagocyte cell engagers (PCEs).
• Analysis of clinical trial data and FDA-approved ICE products.
• Investigation of emerging ICE platforms and combination therapies.

Main Results:

• T-cell engagers, particularly bispecific T-cell engagers (BiTEs), are leading the field with innovations enhancing their efficacy in various cancers.
• NKCEs and PCEs are showing promise, especially in overcoming immunosuppressive tumor microenvironments.
• Since 2014, nine ICEs have been FDA-approved, demonstrating a significant impact on cancer treatment, with many more in clinical development.

Conclusions:

• ICEs have transformed cancer therapy by enabling precise targeting and activation of immune cells against tumors.
• Despite challenges like toxicity and limited efficacy in solid tumors, ongoing research in advanced platforms and combination strategies promises to expand their therapeutic potential.
• ICEs are poised to become a fundamental component of personalized, scalable, and effective future cancer treatments.